glp 1 medications for type 2 diabetes A Guide to GLP-1s: Resources and support GLP-1 GLP-1 RA, GIP/GLP-1 RA and

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated

A number of studies has suggested that IR might be the main mechanism of NAFLD (185, 186)

Its official obesity drug, Zepbound, went on sale in December 2023 and went into shortage by April 2024

Given existing evidence, triple combination therapy can be expected to provide additional cardiorenal protection, although further randomized controlled trials are needed to determine whether triple combination therapy actually has additive or synergetic effects compared with mono or dual therapy

Below are the some GLP-1 medications available in the market currently

GLP-1 receptors (GLP-1R) are distributed across various organs in the human body